Figure 5
Survival after SCT. Two or more cycles of nelarabine (solid line), 58% ± 11% after 1 year, 41% ± 11% after 3 years (N = 19); 1 cycle of nelarabine (dashed line), 32% ± 11% after 1 and 3 years (N = 17). P > .05
Survival after SCT. Two or more cycles of nelarabine (solid line), 58% ± 11% after 1 year, 41% ± 11% after 3 years (N = 19); 1 cycle of nelarabine (dashed line), 32% ± 11% after 1 and 3 years (N = 17). P > .05
